ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 808

A Genome Wide Association Study Of Rheumatoid Arthritis Without Antibodies Against Citrullinated Peptides

Lara Bossini-Castillo1, Carolien de Kovel2, Henrik Kallberg3, Marieke J.H. Coenen4, Paul P. Tak5, Marcel D. Posthumus6, Cisca Wijmenga7, Thomas W.J. Huizinga8, Annette H.M. van der Helm-van Mil9, Luis Rodriguez-Rodriguez10, Isidoro Gonzalez-Alvaro11, Miguel Angel Gonzalez-Gay12, Irene E. van der Horst-Bruinsma13, B.a.C Dijkmans14, G. J. Wolbink15, Roel A. Ophoff2, Piet L.C.M. van Riel16, Lars Klareskog3, J.B.a. Crusius17, Elisabeth Brouwer18, Javier Martin19, Niek de Vries5, René E.M. Toes9, Leonid Padyukov20 and Bobby P.C. Koeleman21, 1Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, 2Department of Medical Genetics, UMCU Utrecht, Utrecht, Netherlands, 3Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 4Human Genetics (855), Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 5Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 6Department of Rheumatology, University of Groningen, University Medical Center, Groningen, Netherlands, 7Department of Genetics, University Medical Hospital Groningen, University of Groningen, Groningen, Netherlands, 8Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 9Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 10Hospital Clínico San Carlos, Department of Rheumatology, Madrid, Spain, 11Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain, 12Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander, Santander, Spain, 13Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 14Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 15Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 16Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 17Pathology, VU University Medical Center, Amsterdam, Netherlands, 18Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 19Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, 20Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 21Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, GWAS, human leukocyte antigens (HLA) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Autoantibodies and Citrullinated Proteins

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA) is a common autoimmune disease that is associated with a progressive loss of the joints induced by a chronic inflammation of the joint synovium. The production of anti-citrullinated peptide/protein antibodies (ACPA) is a common but not essential characteristic of RA patients, which is thought to be influenced by the genetic background. To date, the genetic background of ACPA negative patients (ACPA-) remains widely unknown. Therefore, our goal was to analyze the genetic risk factors that contribute to ACPA- RA.

Methods: We performed a large scale genome wide association study in three European cohorts comprising 1,148 ACPA- RA patients and 6,008 controls. Meta-analysis with previously published data was performed as follow-up for selected signals (reaching a total of 1,922 ACPA- RA patients and 7,087 controls). The HLA region underwent a specific imputation process which inferred the classical HLA alleles, polymorphic amino acid positions and SNPs. Finally, we recursively searched for models which better explained the association in the HLA region following a step-wise strategy.

Results: The combined analysis of the three cohorts identified a peak of association in the HLA-region and 34 non-HLA loci showed suggestive associations. These signals were selected for follow-up using meta-analysis with a previous report. The meta-analysis confirmed the association of the HLA region, a suggestive association in the CLYBL locus (rs9557321, p = 5.82×10-8) and two tier 2 associations (rs518167 in GRM5; rs3790022 in the RNASEH2B-FAM124A region). In addition, we observed nominal associations in previously known susceptibility loci. In the case of the TNPO3–IRF5 region, rs12531711 showed a remarkable risk association with ACPA- RA in the combined analysis (p = 4.35×10-5).

After the imputation in the HLA region, the most significant association corresponded to the HLA-DRB1 Leu67 variant (p-value = 9.41×10-10). Furthermore, we identified two additional independent amino acid signals: HLA-B Asp9 and HLA-DRB1 Thr181. Finally, we confirmed that the model including all the previously mentioned amino acid variants was the most parsimonious explanation and accounted for the observed genome-wide associations in this region.

Conclusion: The present report analyzed the genetic component of a large cohort of ACPA- RA patients compared to non-affected controls following a genome-wide strategy. Our results replicated previous findings in different loci and revealed a novel suggestive susceptibility factor, CLYBL. Moreover, we provided a deep insight into the influence of the HLA region in ACPA- RA. This study supported the existence of an ACPA- specific genetic component and highlighted the importance of comprehensive genetic analysis of large ACPA- RA cohorts.


Disclosure:

L. Bossini-Castillo,
None;

C. de Kovel,
None;

H. Kallberg,
None;

M. J. H. Coenen,
None;

P. P. Tak,
None;

M. D. Posthumus,
None;

C. Wijmenga,
None;

T. W. J. Huizinga,
None;

A. H. M. van der Helm-van Mil,
None;

L. Rodriguez-Rodriguez,
None;

I. Gonzalez-Alvaro,
None;

M. A. Gonzalez-Gay,
None;

I. E. van der Horst-Bruinsma,
None;

B. A. C. Dijkmans,
None;

G. J. Wolbink,
None;

R. A. Ophoff,
None;

P. L. C. M. van Riel,
None;

L. Klareskog,
None;

J. B. A. Crusius,
None;

E. Brouwer,
None;

J. Martin,
None;

N. de Vries,
None;

R. E. M. Toes,
None;

L. Padyukov,
None;

B. P. C. Koeleman,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-genome-wide-association-study-of-rheumatoid-arthritis-without-antibodies-against-citrullinated-peptides/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology